National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

IMP321
A T-cell immunostimulatory factor derived from the soluble form of lymphocyte-activation gene 3 (LAG-3) protein with potential antineoplastic activity. Upon administration, alone or in combination with tumor antigens, IMP321 binds, with high affinity, to MHC class II molecules expressed by dendritic cells (DC), which may result in DC maturation, DC migration to lymph nodes, enhanced DC cross-presentation of antigens to T cells, and antitumor cytotoxic T cell responses. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Foreign brand name:ImmuFact



Previous:Immucell WGP, immunoadjuvant QS-DG, immunotherapy regimen MKC-1106-MT, Immunox, Imodium A-D
Next:Imprime PGG, IMT-1012 immunotherapeutic vaccine, Imuran, inalimarev, Inapsine

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov